✦ LIBER ✦

The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: Where the rubber meets the road

✍ Scribed by Bathon, Joan M. ;Cohen, Stanley B.

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 51 KB
Volume: 59
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.23723

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

American College of Rheumatology 2008 re

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis

✍ Saag, Kenneth G. ;Teng, Gim Gee ;Patkar, Nivedita M. ;Anuntiyo, Jeremy ;Finney, 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 1 views

Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be v

Inclusion of glucocorticoids in recommen

Inclusion of glucocorticoids in recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: Comment on the article by Saag et al

✍ van Tuyl, L. H. D. ;Lems, W. F. ;Voskuyl, A. E. ;Dijkmans, B. A. C. ;Boers, M. ; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB 👁 2 views

Safety of the selective costimulation mo

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

✍ M. Weinblatt; B. Combe; A. Covucci; R. Aranda; J. C. Becker; E. Keystone 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 1 views

Comparison of the response to infliximab

Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register

✍ Kimme L. Hyrich; Deborah P. M. Symmons; Kath D. Watson; Alan J. Silman; British 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract ## Objective To compare outcome at 6 months in unselected “real‐world” patients with rheumatoid arthritis treated with etanercept or infliximab as either monotherapy, cotherapy with methotrexate (MTX), or cotherapy with another disease‐modifying antirheumatic drug (DMARD). ## Methods